Latasopt

Latasopt (Eye Drops)
(Latanoprost)

 

COMPOSITION
Each ml contains latanoprost 0.05 mg.

THERAPEUTIC INDICATIONS
- Increased IOP in patients with open-angle glaucoma and enhanced IOP;
- Tolerance to other drugs decreasing IOP and their low efficiency.

CONTRAINDICATIONS
- Increased sensitivity to drug component.

ADVERSE EFFECTS
Eye irritation (burning, itch, feeling of foreign substances after instillation), and also blackout, thickening and lengthening of eyelashes. Conjunctival hyperemia, transitory dotted epithelial erosions, blepharitis, increase of iris pigmentation.

DOSAGE AND ADMINISTRATION
Only for local use.
Drug is put in conjunctival sac of affected eye in dose 1 drop, 1 time a day in the evening. In case of missing dose the next administration is conducted in a usual regime (the dose is not doubled). The interval between instillations must be not less than 10 minutes at the co-administration of other topical ophthalmologic drugs.

DRUG INTERACTIONS
Latasopt is not pharmaceutically incompatible thimerosal, as possible precipitation.
Drug can be also co-administered with medicines decreasing IOP (timolol, adrenoceptor agonist, acetasolamid, pilokarpin).

PARTICULAR INDICATIONS
Before treatment the patients should be informed about the possibility of eye color changes. The treatment can be discontinued in case of intensive change of eye pigmentation. Using contact lens, they should be put down before dropping and again put on not early than in 15-20 minutes after drug instillation.

PREGNANCY AND LACTATION
Latasopt may be used during pregnancy, when supposed usefulness for mother exceeds the potential risk for fetus. The drug should be carefully administered during lactation period as latanoprost and its metabolites can be excreted with human milk.

MANUFACTURED FORM
2.5 ml plastic vial with a dropper and screwing protective cap, equipped with protective ring.
1 vial in a carton box together with application instruction